Gilead Sciences, Inc. (NASDAQ:GILD) is one of the 10 Safest Dividend Stocks to Buy Right Now.
On May 21, 2026, Gilead Sciences, Inc. (NASDAQ:GILD) announced that the company, together with its subsidiary Kite, will present over 25 abstracts at the 2026 ASCO Annual Meeting (May 29 – June 2) and the EHA Congress (June 11 – 14), showcasing progress in cancer therapies
Key ASCO presentations include new late-stage Phase 3 analyses for Trodelvy in first-line metastatic triple-negative breast cancer, focusing on long-term progression-free survival. For the first time, Kite will also introduce manufacturing consistency data for anito-cel, an investigational CAR T-cell therapy for multiple myeloma. In addition, EHA updates will showcase the results regarding the durability and safety of an enhanced CAR T-cell therapy called KITE-753 that targets relapsed/refractory B-cell lymphoma.
In a recent development, Gilead Sciences, Inc. (NASDAQ:GILD) announced new Phase 3 interim data showing Livdelzi achieved high and sustained normalization of a key liver marker (ALP) in primary biliary cholangitis patients. According to the results, the drug was well-tolerated over two years of treatment. Founded in 1987 and headquartered in California, Gilead Sciences Inc. (NASDAQ:GILD) is a drug manufacturer that develops medicines for unmet medical needs.